Suchen
Passage Bio Inc
PASGZur Watchlist hinzufügen
4.510USD
-0.370-7.58%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
14.47MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Passage Bio Inc Unternehmen
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Passage Bio Inc Informationen
BörsenkürzelPASG
Name des UnternehmensPassage Bio Inc
IPO-datumFeb 28, 2020
CEOChou (William)
Anzahl der mitarbeiter60
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 28
AddresseOne Commerce Square
StadtPHILADELPHIA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl19103
Telefon12678660312
Websitehttps://www.passagebio.com/
BörsenkürzelPASG
IPO-datumFeb 28, 2020
CEOChou (William)
Führungskräfte von Passage Bio Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. William Chou, M.D.
Mr. William Chou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.72K
+5.95%
Ms. Kathleen Borthwick
Ms. Kathleen Borthwick
Chief Financial Officer
Chief Financial Officer
5.40K
+7.39%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
945.00
--
Mr. Edgar B. (Chip) Cale
Mr. Edgar B. (Chip) Cale
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Mr. Sandip S. Kapadia, CPA
Mr. Sandip S. Kapadia, CPA
Independent Director
Independent Director
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Chairwoman of the Board
Independent Chairwoman of the Board
--
--
Dr. Derrell D. Porter, M.D.
Dr. Derrell D. Porter, M.D.
Independent Director
Independent Director
--
--
Dr. Dolan Sondhi, Ph.D.
Dr. Dolan Sondhi, Ph.D.
Independent Director
Independent Director
--
--
Mr. Thomas Kassberg
Mr. Thomas Kassberg
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. William Chou, M.D.
Mr. William Chou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.72K
+5.95%
Ms. Kathleen Borthwick
Ms. Kathleen Borthwick
Chief Financial Officer
Chief Financial Officer
5.40K
+7.39%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
945.00
--
Mr. Edgar B. (Chip) Cale
Mr. Edgar B. (Chip) Cale
General Counsel, Company Secretary
General Counsel, Company Secretary
--
--
Mr. Sandip S. Kapadia, CPA
Mr. Sandip S. Kapadia, CPA
Independent Director
Independent Director
--
--
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Chairwoman of the Board
Independent Chairwoman of the Board
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Passage Bio Inc?
Die fünf größten Anteilseigner von Passage Bio Inc sind: Mr. William Chou, M.D.
Wie viele Institutionen halten Anteile an Passage Bio Inc (PASG)?
Mit Stand vom 2026Q1 halten 94 Institutionen Anteile an Passage Bio Inc, mit einem Gesamtmarktwert von etwa 1.82M, was 56.60% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -203071.00 gestiegen.